Recorded fact · drug.trial_access

drug.trial_access for pomalidomide

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact eb56705a resolves to.

The record

Fact id	`eb56705a0af30bb86a912bfe`
Entity	drug: pomalidomide
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "POMALIDOMIDE",
 "recruitingInterventionalCount": 57,
 "notYetRecruitingCount": 13,
 "byPhase": {
  "PHASE3": 16,
  "PHASE1": 9,
  "PHASE2": 15,
  "PHASE1/PHASE2": 13,
  "NA": 3,
  "PHASE2/PHASE3": 1
 },
 "trials": [
  {
   "nctId": "NCT05730036",
   "briefTitle": "A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Regeneron Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2023-09-18",
   "conditions": [
    "Relapsed Refractory Multiple Myeloma (RRMM)"
   ],
   "countries": [
    "United States",
    "Australia",
    "Belgium",
    "Brazil",
    "Canada",
    "Chile",
    "France",
    "Germany",
    "Israel",
    "Italy"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05730036"
  },
  {
   "nctId": "NCT05137054",
   "briefTitle": "A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Regeneron Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2022-08-17",
   "conditions": [
    "Multiple Myeloma"
   ],
   "countries": [
    "United States",
    "France",
    "Greece",
    "Israel",
    "Spain"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05137054"
  },
  {
   "nctId": "NCT07825064",
   "briefTitle": "Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2026-11-03",
   "conditions": [
    "Multiple Myeloma"
   ],
   "countries": [
    "Germany"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07825064"
  },
  {
   "nctId": "NCT06948084",
   "briefTitle": "Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "National Cancer Institute (NCI)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2027-05-22",
   "conditions": [
    "Recurrent Multiple Myeloma",
    "Refractory Multiple Myeloma"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06948084"
  },
  {
   "nctId": "NCT07222761",
   "briefTitle": "A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Regeneron Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2026-01-02",
   "conditions": [
    "Relapsed and/or Refractory Multiple Myeloma (RRMM)"
   ],
   "countries": [
    "United States",
    "Australia",
    "Brazil",
    "Chile",
    "South Korea",
    "Taiwan",
    "Turkey (Türkiye)",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07222761"
  },
  {
   "nctId": "NCT06106945",
   "briefTitle": "AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "AstraZeneca",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2023-12-05",
   "conditions": [
    "Multiple Myeloma"
   ],
   "countries": [
    "United States",
    "Australia",
    "Brazil",
    "Canada",
    "China",
    "France",
    "Germany",
    "Japan",
    "Spain",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06106945"
  },
  {
   "nctId": "NCT05519085",
   "briefTitle": "A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Celgene",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2022-09-20",
   "conditions": [
    "Relapsed or Refractory Multiple Myeloma"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Austria",
    "Belgium",
    "Brazil",
    "Canada",
    "Chile",
    "China",
    "Czechia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05519085"
  },
  {
   "nctId": "NCT06615479",
   "briefTitle": "A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-29",
   "startDate": "2025-03-12",
   "conditions": [
    "Relapsed or Refractory Multiple Myeloma (RRMM)"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Austria",
    "Belgium",
    "Brazil",
    "Canada",
    "Czechia",
    "Denmark",
    "Finland"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06615479"
  },
  {
   "nctId": "NCT06953960",
   "briefTitle": "A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)",

... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: 8944619b37667a1e3de9d8a3816d4a01d05e91031e116efc0b46c71f9189fa06.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.